Sign In To Continue
You have reached the guest article limit.
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
The U.S. Patent Trial and Appeal Board (PTAB) has reaffirmed its 2022 decision that the Broad Institute, MIT, and Harvard hold priority for the invention of CRISPR-Cas9 gene editing applications in eukaryotic cells. This ruling follows a remand from the U.S. Court of Appeals for the Federal Circuit, which requested re…
Share This Article
Ready-to-post copy includes the article link.
PTAB Upholds Broad Institute's Priority in CRISPR-Cas9 Patent Dispute with University of California The U.S. Patent Trial and Appeal Board (PTAB) has reaffirmed its 2022 decision that the Broad Institute, MIT, and Harvard hold priority for the invention of CRISPR-Cas9 gene editing applications in eukaryotic cells. Thi... Read the full IIPLA article: https://iipla.org/news/ptab-upholds-broad-institute-s-priority-in-crispr-cas9-patent-dispute-with-university-of-california